Featured Articles

  1. Including Diversity At The Onset 6/13/2024

    Designing a clinical protocol that is fit for purpose can incorporate diversity into clinical trial planning early on. Explore strategies for incorporating diversity into clinical planning and study protocols.

  2. Cell And Gene Therapy Field Gains Momentum 6/13/2024

    Discover how the dynamic growth trajectory of this field underscores its potential to revolutionize medicine and deliver innovative treatments to patients worldwide.

  3. Completed Clinical Trials, Terminations Both Rose In 2023 6/13/2024

    This white paper highlights how the widespread growth in completed trials is coupled with higher success rates across multiple therapeutic areas, signaling the end of pandemic-related disruptions and infectious disease-related activity after three years of fluctuations.

  4. Pharma R&D Review 2024: Pleasant Weather Ahead 5/16/2024

    Gain insights from the 2024 pharma landscape, which reports a record-breaking 22,825 pipeline drugs, led by Pfizer's 32 new candidates and a strong focus on oncology and neurological treatments.

  5. Optimizing Recruitment For Urgently Needed Vaccine 5/15/2024

    Uncover how Citeline Connect helped a late-stage biotech sponsor expedite enrollment of a diverse population of eligible patients impacted by monkeypox for a large Phase 1 and Phase 2 trial of a next-generation vaccine.

  6. Deal-Making Volume Slowed In 2023 5/15/2024

    This report provides an overview of alliance, merger and acquisition, and financing deal activities across the global biopharma, medical device, and in vitro diagnostics industries in 2023, as reported by Biomedtracker.

  7. Backup Sites: The Closers Of Clinical Trials 4/22/2024

    Backup or coverage sites are usually brought in at the same time as others but are not activated. These sites become add-on or rescue sites, or the clinical equivalent of baseball’s ninth inning.

  8. Pharma R&D Annual Review 2024 4/22/2024

    As we reflect on the past year's accomplishments and challenges, our insights serve as a beacon for driving innovation, fostering collaboration, and advancing global healthcare outcomes.

  9. Considerations For Plain Language Summaries 4/22/2024

    Recent FDA emphasis on plain language underscores a shift towards greater transparency and patient understanding, highlighted in the joint FDA and Office for Human Research Protections (OHRP) draft guidance.

  10. Diversity In Clinical Trials: Walking The Walk 4/22/2024

    Discover why achieving true diversity demands more than rhetoric—requiring genuine engagement, cultural humility, and a commitment to understanding and addressing the unique needs of marginalized communities.